X

Drug Profile

IMB 1003

Alternative Names: IMB-1003

Latest Information Update: 19 Oct 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator IMIDomics
Class Anti-inflammatories; Proteins
Mechanism of Action B cell inhibitors; Natural killer cell inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Research Crohn's disease; Systemic lupus erythematosus

Most Recent Events

11 Oct 2023 IMB 1003 is available for licensing as of 13 Oct 2023. https://www.imidomics.com/partnerships
11 Oct 2023 IMIDomics in-licenses innovative drug development technology from University of Barcelona
11 Oct 2023 Early research in Crohn's disease in Spain (Parenteral) (IMIDomics pipeline, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com